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Modulating protein activity using tethered ligands
with mutually exclusive binding sites
Alberto Schena1,2,3,*, Rudolf Griss1,2,3,* & Kai Johnsson1,2,3
The possibility to design proteins whose activities can be switched on and off by unrelated
effector molecules would enable applications in various research areas, ranging from
biosensing to synthetic biology. We describe here a general method to modulate the activity
of a protein in response to the concentration of a speciﬁc effector. The approach is based on
synthetic ligands that possess two mutually exclusive binding sites, one for the protein of
interest and one for the effector. Tethering such a ligand to the protein of interest results in an
intramolecular ligand–protein interaction that can be disrupted through the presence of the
effector. Speciﬁcally, we introduce a luciferase controlled by another protein, a human
carbonic anhydrase whose activity can be controlled by proteins or small molecules in vitro
and on living cells, and novel ﬂuorescent and bioluminescent biosensors.
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A
llosteric proteins act as molecular switches in which
binding of a molecule to a site different from the active
site changes the conformation of the protein and its
underlying activity. Such proteins are fundamental for the
regulation of most natural signalling processes. Designing new
allosteric proteins is a formidable test for our understanding of
protein function and such designer proteins can ﬁnd applications
in synthetic biology and biosensing1–4. For example, the most
popular ﬂuorescence-based biosensor for live-cell imaging is
based on an engineered ﬂuorescent protein allosterically regulated
by calcium ions5.
The design of novel allosteric proteins is usually based on the
insertion of a pre-existing allosteric protein domain into another
protein; binding of the allosteric modulator then changes the
conformation of the allosteric domain and of the protein in which
it is inserted6–8. However, the generality of the approach is
limited as it relies on pre-existing allosteric proteins and
modulators. In addition, the identiﬁcation of an appropriate
insertion site is difﬁcult. Alternative approaches for regulating
protein activity have been developed. For example, enzymatic
activities have been regulated by tethering an inhibitor to an
enzyme through a single-stranded oligonucleotide; binding of a
complementary DNA sequence prevents an intramolecular
inhibition of the enzyme9,10. However, in its present form the
approach is limited to DNA as an effector molecule. In another
approach, the activity of an enzyme is regulated by introducing
new binding sites in close proximity to its active site11. This
principle is the basis for the enzyme multiplied immunoassay
technique—the ﬁrst homogeneous immunoassays—which are
still commonly used in diagnostics today12,13. However, not every
enzyme lends itself to such modiﬁcations of its active site. In
short, alternative design principles for the generation of proteins
that can exist in two different states that are energetically similar
but differ in activity are needed.
We introduce here a conceptually novel approach to regulate
protein activity. As with allosteric proteins, the activity of
the reporter is modulated by an external effector. However, the
modulation is not based on a conformational change within the
reporter protein but on the steric displacement of a ligand in a
larger semisynthetic protein construct. This is achieved by
generating synthetic ligands that possess two mutually exclusive
binding sites. We demonstrate the potential of the approach by
generating a novel bioluminogenic protein as well as biolumi-
nescent and ﬂuorescent biosensors for applications in vitro
and in live cells.
Results
Effector-modulated reporters. We have previously introduced
ﬂuorescent and bioluminescent sensor proteins that are based on
the competition of a tethered ligand with an analyte for a com-
mon binding site14–18. The binding and unbinding of the tethered
ligand leads to a change in ﬂuorescence resonance energy transfer
(FRET) or bioluminescence resonance energy transfer (BRET)
efﬁciency and can be used as readout for the concentration of the
competing analyte. We speculated that adding a second synthetic
ligand that binds to its target in a mutually exclusive manner with
respect to the ﬁrst tethered ligand could allow the modulation of
protein activity by an unrelated effector. In this approach, the
effector binds to one of the two synthetic ligands, making the
other one unavailable for interactions with the protein to which
the synthetic ligands are tethered. The task of modulating protein
activities is thus reduced to either the modiﬁcation of an existing
ligand–protein interaction or the design of a new one and opens
up the possibility to transform regular proteins into effector-
modulated reporters resembling allosteric proteins. In the
following, we will abbreviate our approach as chemical ligand-
associated steric hindrance (CLASH).
Control of a luciferase by an exogenous effector. Controlling the
light-emitting properties of luciferases through molecules of
interest is an attractive approach to generate powerful biosensors.
Luciferases allosterically controlled by either calcium ions or cyclic
AMP have been generated by inserting naturally occurring allos-
teric protein domains19,20, but to the best of our knowledge no
luciferases have been designed that are regulated by other proteins.
We thus exploited CLASH to transform the luciferase from Renilla
reniformis into one that is activated by an effector protein. For ﬁrst
proof-of-principle experiments, we chose the protein streptavidin
as the effector, since its natural ligand biotin can be readily
synthetically derivatized. We synthesized a dual ligand containing
the luciferase inhibitor coelenteramide21 and biotin in such close
proximity that simultaneous binding to the luciferase and to
streptavidin should be disfavoured (Fig. 1a,b). Using SNAP-tag
technology22, we chemically linked the dual ligand to the
R. reniformis luciferase, generating CLASH-Strep/Luc (Fig. 1c).
In the absence of streptavidin, the tethered coelenteramide
inhibits the luciferase, resulting in a dark state. On addition of
streptavidin, the light intensity increased in a concentration-
dependent manner: binding of streptavidin to the biotin moiety of
the synthetic ligand forces coelenteramide to dissociate from the
luciferase, leading to an active luciferase. The light intensity
increased by 1,700% in the presence of streptavidin, permitting
streptavidin detection by naked eye (Fig. 1d,e). The marked
increase in light emission in response to an analyte makes the
approach an attractive starting point for generating biosensors for
various proteins. This then would require the replacement of
biotin in our synthetic ligand with an appropriate binder to the
protein of interest.
Control of human carbonic anhydrase. To demonstrate the
generality of CLASH, we applied it to regulate the activity of the
enzyme human carbonic anhydrase II (HCA). Furthermore, we
wanted to translate the activity modulation into a signal compa-
tible with biosensing. We synthesized a dual ligand in which the
HCA inhibitor benzenesulfonamide and a biotin moiety are
connected in a way that binding to their respective protein
receptors would be mutually exclusive (Fig. 2a–c) and used again
streptavidin as the effector. The choice of the linker composition
and length in the labelling molecule was based on the crystal
structure of the receptor proteins. To couple HCA activity
switching to a readout compatible with biosensing, we expressed
HCA as a fusion protein with the luciferase NanoLuc, a
30-proline linker (PP30) and SNAP-tag, following the design
principles of LUCIDs—our previously described class of
BRET-based biosensors18. The SNAP-PP30-NLuc-HCA fusion
protein was labelled with the synthetic ligand also containing
the ﬂuorophore Cy3 for the BRET readout. The resulting
semisynthetic protein CLASH-Strep/HCA (Fig. 2b) is expected
to show an increase in HCA activity and display a change in
BRET efﬁciency between NanoLuc and Cy3 when the tethered
ligand is displaced from HCA through binding of the effector
streptavidin. The interaction between streptavidin and biotin has a
Kd in the femtomolar range; since this is much lower than the
concentration of CLASH-Strept/HCA in the assay, the transition
of the titration curve occurs around the concentration of the
CLASH construct.
To assess the control of HCA activity in CLASH-Strep/HCA,
we performed a standard HCA activity assay based on the
catalysis of a chromogenic reaction23. In the absence of
streptavidin, the construct showed low HCA activity, but on
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addition of saturating concentrations of streptavidin, the
catalytic activity was restored (Fig. 2d). This is in agreement
with an inhibition of the HCA activity through the intra-
molecular benzenesulfonamide in the absence of streptavidin,
while on binding of streptavidin to the dual ligand, the
benzenesulfonamide is displaced from HCA and the hydrolytic
activity is restored. We also tested CLASH-Strep/HCA for BRET
efﬁciency changes at increasing concentrations of streptavidin.
We measured an overall BRET ratio change of 640±50%
(Fig. 2e,f). The same ratio change was measured when opening
CLASH-Strep/HCA by addition of high concentrations of the
HCA inhibitor benzenesulfonamide (Supplementary Fig. 1),
conﬁrming that the binding of streptavidin to biotin indeed
leads to the unbinding of benzenesulfonamide from HCA. When
the synthetic ligand BG-Cy3-SA that lacks the biotin moiety
was used to label the protein, no response to streptavidin was
observed (Fig. 2f).
To demonstrate the modularity of our approach, we took the
same HCA fusion protein as above, but used the enzyme
dihydrofolate reductase (DHFR) as the effector. Towards
this end, we labelled SNAP-PP30-NLuc-HCA with a synthetic
ligand that consists of the DHFR-ligand trimethoprim and
benzenesulfonamide, generating CLASH-DHFR/HCA (Fig. 3a,b).
In the absence of DHFR, the benzenesulfonamide occupies the
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Figure 1 | Control of a luciferase. (a) Schematic principle of the regulation of a luciferase by an exogenous effector: the dual ligand coelenteramide/biotin
can bind to luciferase (Luc) or streptavidin (Strep) separately but not to both at the same time. Binding of streptavidin to the secondary ligand biotin (B)
makes the tethered coelenteramide (C) unbind from the luciferase active site, leading to a change in bioluminescence. (b) Crystal structures of the active
sites of Renilla luciferase with the inhibitor coelenteramide (blue, PDB ID 2PSJ) and of streptavidin bound to biotin (green, PDB ID 3RY2). (c) Structure of
the dual ligand labelling molecule. (d) Luminescence intensity of 100 ml of 25 nM CLASH-Strep/Luc mixed with 2.5mgml 1 of the substrate coelenterazine
in absence and in presence of 1 mM streptavidin. (e) Picture of the same solutions in transparent tubes, taken with a Canon 600D camera.
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active site of HCA and CLASH-DHFR/HCA is in a closed
conformation, as shown by the high BRET efﬁciency (Fig. 3c). In
the presence of sufﬁcient concentrations of DHFR, the binding of
the tethered sulfonamide to the active site of HCA is prevented
and CLASH-DHFR/HCA adopts an open conformation, as
demonstrated by its low BRET efﬁciency.
By mixing CLASH-DHFR/HCA with a deﬁned concentration
of free DHFR, CLASH-DHFR/HCA can be easily transformed
into a biosensor for DHFR ligands such as the anticancer agent
methotrexate (MTX), commonly monitored in hospital
patients24. DHFR brings the sensor molecule into its open
conformation and can be displaced by MTX. If the concentration
of MTX is lower than the concentration of free DHFR, the drug is
quantitatively bound to DHFR, while above this threshold the
excess of free MTX disrupts the interaction between DHFR and
tethered trimethoprim, thereby bringing CLASH-DHFR/HCA to
its high-BRET state. At the stage where all free DHFR is bound to
MTX, only a small relative increase in MTX concentration is
necessary to displace the DHFR bound to the sensor molecule,
giving a sharp transition. The transition can be easily seen with
the naked eye and can be shifted by simply changing the
concentration of free DHFR (Fig. 3d; Supplementary Fig. 2).
While a similar system could also be obtained using the
previously introduced DHFR-based LUCID for MTX18, the
present approach opens up the possibility to construct
ratiometric BRET sensors with binding proteins that are
geometrically not well suited for LUCID sensors. For example,
an antibody can replace the free DHFR and one of the two binding
sites of our synthetic ligand can be the antigen. The plethora of
commercially available antibodies would allow transforming
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CLASH-antigen/HCA into biosensors for a multitude of analytes.
We demonstrated this principle by titrating CLASH-Strep/HCA
with anti-biotin monoclonal antibody. In accordance with the
CLASH principle, at increasing concentrations of the antibody the
BRET efﬁciency decreases (Supplementary Fig. 3).
Use of CLASH in live-cell imaging. Labelling of SNAP-tag
fusion proteins can be achieved in vitro and in vivo, including
whole animals25. While the low permeability of the synthetic
ligands we describe here would make intracellular applications
difﬁcult, the selectivity of the labelling reaction opens up the
possibility to generate effector-regulated proteins on the surface
of living cells, either to control protein activities or for sensing
applications. To demonstrate this possibility, we aimed at
displaying a CLASH-AChE/HCA on HEK293 cells in which the
activity of HCA is regulated by compounds targeting
acetylcholine esterase (AChE). Controlling the activity of an
enzyme such as HCA that is part of a family of closely related
enzymes is difﬁcult since speciﬁc inhibitors are rarely available.
Achieving control with an unrelated compound that does not
interact with any other member of such family is of interest for
mechanistic studies. As compounds targeting AChE are used as
drugs, pesticides or nerve agents, our CLASH-AChE/HCA could
in addition be used for biosensing applications. We have
previously reported a FRET-based biosensor for detecting such
compounds, ACh-SNIFIT26, which however suffered from
relatively small ratio changes16.
To create CLASH-AChE/HCA, AChE was fused to the
N-terminus of an HCA-based SNIFIT (Fig. 4a). We targeted
the construct to the outer cell membrane of transiently
transfected HEK293 cells. The cells were labelled with a dual
ligand containing benzenesulfonamide as primary ligand and
edrophonium, an inhibitor of AChE26, as secondary ligand
(Fig. 4b). In the absence of free AChE inhibitors, the stronger
interaction of edrophonium with AChE prevents the binding of
the primary ligand to HCA, keeping the sensor in its low-FRET
state. When the AChE inhibitor tacrine, a drug used in the past to
treat Alzheimer’s disease, was perfused on living cells expressing
CLASH-AChE/HCA, tacrine displaced the secondary ligand from
AChE, allowing the benzenesulfonamide to bind HCA and
leading to high FRET efﬁciency of the sensor (Fig. 4c-d).
Importantly, the switching between the two states was fully
reversible, and the overall measured FRET ratio change was
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twofold higher than the original ACh-SNIFIT26. In CLASH-
AChE/HCA, the relative strength of the two synthetic ligands is
such that HCA is active in the absence of the effector targeting
AChE and inhibited by its addition (see also Supplementary
Discussion for a more detailed discussion of the underlying
design principles). Choosing a stronger HCA ligand, it
should be equally possible to generate a variant, namely
CLASH-HCA/AChE, in which AChE activity is controlled by
small benzenesulfonamides. As AChE is a key enzyme for
neurotransmission both at the central and at the peripheral
nervous systems, such a CLASH-HCA/AChE could ﬁnd
applications as a research tool in neurobiology. For example,
inactivating its AChE activity by the addition of a biorthogonal
small molecule, for example, a sulfonamide, could help in
elucidating the role of cholinergic pathways in neurobiology.
Discussion
In conclusion, CLASH represents a general concept to control
protein function in response to an unrelated effector. The
approach allowed us to transform a regular luciferase in a
bioluminogenic probe responding with marked increase in
emitted light on addition of a regulator. We applied the same
principle to control the activity of the enzyme HCA by three
completely different ligands, two proteins and a small molecule.
The possibility to modulate protein activities on the surface
of living cells opens up applications beyond in vitro assays.
While the feasibility of our approach was demonstrated for a
number of unrelated proteins, we would like to reiterate that it is
restricted to proteins for which ligands with mutually exclusive
binding sites exist or can be designed. Finally, this work highlights
how the combination of synthetic chemistry and protein
engineering can be exploited to create proteins with entirely
new functionalities.
Methods
Synthesis of the labelling compounds. Detailed procedures for the synthesis of
all compounds and SNAP-tag substrates, their characterization, the titration in
multiwell plates and the imaging experiments are given in the Supplementary
Methods.
a
b
d
BG-Cy5-SA/Edro
c
BG
Cy5
SA
E
Cy3 Cy5 Overlay
N
o 
ta
cr
in
e
3 
m
M
 ta
cr
in
e
N
S
O
O
–O
S
O
O O–
O
N+
O
HNNHHN
O
O
O
11
N
H
O
NH
O
S
NH2
O
O
O
H
N N
O OH
N+
N
NN
N
H NH2
O N N
AChE
SNAP HCA
Pro30
E   T
CLIP
HC
A
E
SNAP
FRET
AChE
CLIP
T
SA
SA
3 mM tacrine
0 120 240 360 480 600
0.2
0.4
0.6
0.8
1.0
0.7
0.8
0.9
1.0
0 100 200 300 400 500 600
0 100 200 300 400 500 600
1.0
1.1
1.2
1.3
R
at
io
D
on
or
 (a
.u.
)
Time (s)
Ac
ce
pt
or
 (a
.u.
)
Pro30
Figure 4 | Modulation of HCA by tacrine on living cells. (a) Cartoon of CLASH-AChE/HCA. The acetylcholine esterase (AChE) inhibitor tacrine (T)
displaces edrophonium (E) from AChE and benzenesulfonamide (SA) can bind to HCA inducing an increase in FRETefﬁciency. (b) Structure of the labelling
compound. (c) Fluorescence micrographs of HEK293 cells displaying CLASH-AChE/HCA on their surface. In the absence of tacrine Cy3 emission is more
intense, while on addition tacrine Cy5 emission increases; scale bars, 50mm. (d) Changes observed in FRETratio, donor (Cy3) and acceptor (Cy5) emission
on perfusion of HEK293 cells displaying CLASH-AChE/HCA on their surface with 3mM tacrine.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8830
6 NATURE COMMUNICATIONS | 6:7830 |DOI: 10.1038/ncomms8830 |www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
Cloning and protein expression. All sensor constructs were obtained from
the pET51b(þ )-based construct SNAP-PP30-NLuc-HCA described in ref. 18 or
from pDisplay-based construct SNAP-PP30-CLIP-HCA16 using standard
cloning techniques. The amino-acid sequences of the described proteins can be
found in Supplementary Note 1. The proteins were expressed in the Escherichia coli
strain Rosetta-gami (DE3). Bacterial cultures in LB or 2YT medium were
grown at 37 C to an OD600 nm of 0.8, at which point the temperature was lowered
to 16 C, and 0.5mM isopropyl b-D-thiogalactopyranoside was added. After 16 h,
the cells were harvested by centrifugation and lysed by sonication. The cell
extracts were cleared by centrifugation and puriﬁed in two steps using Ni-NTA
(Qiagen) and Strep-Tactin (IBA) according to the suppliers’ instructions. The
proteins were then transferred into HEPES buffer (50mM HEPES, pH 7.2, 50mM
NaCl) using Amicon Ultra-0.5 Ultracel-30K centrifugal ﬁlters (Millipore).
Solutions with proteins containing HCA were supplemented with a twofold
molar excess of ZnCl2.
SNAP-tag labelling. The sensor proteins were diluted to 1 mM in HEPES buffer
containing 4 mM of the corresponding SNAP-tag substrate. After incubation at
room temperature for 1 h, the labelled sensor constructs were puriﬁed using
Amicon Ultra-0.5 Ultracel-30K centrifugal ﬁlters (Millipore), washing three times
with 0.4ml HEPES buffer.
Luciferase activity assay. The labelled protein SNAP-hRLuc was diluted to a
concentration of 50 nM in HEPES buffer with or without 2 mM streptavidin
(New England Biolabs). One hundred microlitres were added to the wells of a white
nonbinding 96-well plate (Greiner Bio-One). The luciferase activity was then
measured on an EnVision Multilabel Reader (PerkinElmer): 100 ml of 5mg l 1
benzyl coelenterazine (NanoLight Technology) was added to the wells using the
system’s injector and the luminescence intensity was measured after 5 s. Photo-
graphs were taken with a Canon 600D digital camera.
HCA activity assay. HCA hydrolytic activity assays were performed using the
standard p-nitrophenyl acetate assay23: 1 mM of the protein was mixed with
1mM p-nitrophenyl acetate in HEPES buffer. The rates of the HCA catalysed
reactions were measured by following the absorbance at 348 nm characteristic
of the reaction product using a SPECTRAmax 340 spectrophotometer (Molecular
Devices).
BRET assays. The labelled proteins were diluted to concentrations of 20 nM in
50ml HEPES buffer containing 0.5mgml 1 bovine serum albumin and spiked
with known concentrations of analyte in white nonbinding 96-well plates (Greiner
Bio-One). After incubation at room temperature for 15–30min, 50 ml Nano-Glo
Luciferase Assay Substrate (Promega) diluted 50-fold in Nano-Glo Luciferase
Assay Buffer (Promega) was added. Bioluminescence was measured on an
EnVision Multilabel Reader (PerkinElmer). The signal was collected using an
emission ﬁlter for Umbelliferone (wavelength: 460 nm and bandwidth: 25 nm) to
record NanoLuc emission and a ﬁlter for Cy3 (wavelength: 595 nm and bandwidth:
60 nm) to record Cy3 emission. Emission spectra were measured on an Inﬁnite
M1000 spectroﬂuorometer (Tecan) with a step size of 1 nm, a bandwidth of
10 nm and an integration time of 100ms. Assays involving DHFR were performed
in the presence of 50 or 100 mM NADPH. Biotin monoclonal antibody (BTN.4)
was purchased from Fischer Scientiﬁc (THERMO SCIENTIFIC PIERCE AB
MA5-11251).
Live-cell FRET imaging. HEK293 cells were grown on polylysine-coated glass
coverslips (Ø 15mm) in DMEM Glutamax medium (Lonza) supplemented with
10% fetal bovine serum (Lonza) and transiently transfected with the appropriate
plasmid using Lipofectamine (Invitrogen) according to the manufacturer’s
protocol. Twenty-four hours after transfection, HEK293 cells were labelled
with a solution of 2 mM of the corresponding BG derivative and 10 mM of the
corresponding O2-benzylcytosine derivative in Hank’s buffered salt solution
complemented with 10mgml 1 bovine serum albumin for 10min at room
temperature. After being labelled, cells were washed four times with Hank’s
buffered salt solution. Glass coverslips with labelled HEK293 cells were transferred
to a Warner imaging chamber (RC-20). Perfusion of the chamber was performed
gravity fed at a ﬂow rate of 0.5mlmin 1. Time-course experiments of sensor
imaging were performed using a Leica LAS AF 7000 wideﬁeld microscope
equipped with a 40 plan Apochromat 1.25 numerical aperture oil immersion
objective lens. A xenon arc lamp was used for imaging of the HEK293 cells. For
each frame, the two channels (donor and FRET) were measured consecutively with
an interval of 30ms between the two emission channels. The following ﬁlter
sets were used for the FRET ratio imaging: for Cy3/Cy5, excitation at 530 nm
(bandwidth 35 nm), emission at 580 nm (bandwidth 40 nm) (Cy3) and at 700 nm
(bandwidth 72 nm) (Cy5). If not indicated otherwise, the image size was
293 293 mM, and an average of ﬁve cells per image was analysed for the intensity
ratio plots.
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